RhumbLine Advisers
STRO icon

RhumbLine Advisers’s Sutro Biopharma STRO Stock Holding History

RhumbLine Advisers’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$685K Buy
+20,628
New +$643K ﹤0.01% 2554
2025
Q2 		– Sell
-12,282
Closed -$79.9K – 4256
2025
Q1 		$79.9K Sell
12,282
-388
-3% -$6.11K ﹤0.01% 3460
2024
Q4 		$233K Buy
12,670
+732
+6% +$22.3K ﹤0.01% 3113
2024
Q3 		$413K Buy
11,938
+328
+3% +$12.9K ﹤0.01% 2836
2024
Q2 		$340K Buy
11,610
+2,194
+23% +$86.8K ﹤0.01% 2927
2024
Q1 		$532K Buy
9,416
+257
+3% +$11.4K ﹤0.01% 2636
2023
Q4 		$393K Sell
9,159
-31
-0.3% -$984 ﹤0.01% 2813
2023
Q3 		$319K Buy
9,190
+225
+3% +$9.8K ﹤0.01% 2898
2023
Q2 		$417K Buy
8,965
+495
+6% +$24.6K ﹤0.01% 2808
2023
Q1 		$391K Buy
8,470
+693
+9% +$44K ﹤0.01% 2523
2022
Q4 		$628K Buy
7,777
+679
+10% +$47.2K ﹤0.01% 2358
2022
Q3 		$394K Buy
7,098
+822
+13% +$48.7K ﹤0.01% 2605
2022
Q2 		$327K Buy
6,276
+758
+14% +$42.3K ﹤0.01% 2715
2022
Q1 		$454K Sell
5,518
-79
-1% -$7.52K ﹤0.01% 2467
2021
Q4 		$833K Buy
5,597
+73
+1% +$13.1K ﹤0.01% 2280
2021
Q3 		$1.04M Buy
5,524
+203
+4% +$38.6K ﹤0.01% 2213
2021
Q2 		$989K Buy
5,321
+2,396
+82% +$469K ﹤0.01% 2254
2021
Q1 		$666K Buy
2,925
+154
+6% +$36.5K ﹤0.01% 2362
2020
Q4 		$602K Buy
2,771
+720
+35% +$119K ﹤0.01% 2363
2020
Q3 		$206K Buy
2,051
+174
+9% +$16.4K ﹤0.01% 2673
2020
Q2 		$146K Buy
1,877
+497
+36% +$47.7K ﹤0.01% 2865
2020
Q1 		$141K Hold
1,380
– – ﹤0.01% 2696
2019
Q4 		$152K Buy
1,380
+22
+2% +$2.27K ﹤0.01% 2812
2019
Q3 		$123K Buy
1,358
+116
+9% +$11.7K ﹤0.01% 2854
2019
Q2 		$141K Buy
+1,242
New +$137K ﹤0.01% 2869

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

RhumbLine Advisers's STRO Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Sutro Biopharma (STRO) in Q2 2026: 20,628 shares worth $685K. The stake represents ﹤0.01% of the portfolio and ranks #2554 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in STRO as recently as Q1 2025.

RhumbLine Advisers first reported a position in STRO in Q2 2019 and has held it in 25 quarters since. The position peaked at $1.04M in Q3 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • RhumbLine Advisers held 20,628 shares of Sutro Biopharma worth $685K as of Q2 2026.
  • Sutro Biopharma was a new RhumbLine Advisers position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2554 holding.
  • RhumbLine Advisers first reported a position in Sutro Biopharma in Q2 2019 and has held it in 25 quarters since.
  • RhumbLine Advisers's Sutro Biopharma position peaked at $1.04M in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.